Andrew D Newton1, Jarrod D Predina2, Christopher J Corbett2, Lydia G Frenzel-Sulyok2, Leilei Xia2, E James Petersson3, Andrew Tsourkas4, Shuming Nie5, Edward J Delikatny6, Sunil Singhal2. 1. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: Andrew.Newton@uphs.upenn.edu. 2. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Department of Chemistry, University of Pennsylvania, Philadelphia, PA. 4. Department of Bioengineering, University of Pennsylvania, Philadelphia, PA. 5. Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL. 6. Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Abstract
BACKGROUND: Near-infrared (NIR) imaging using the second time window of indocyanine green (ICG) allows localization of pulmonary, pleural, and mediastinal malignancies during surgery. Based on empirical evidence, we hypothesized that different histologic tumor types fluoresce optimally at different ICG doses. STUDY DESIGN: Patients with thoracic tumors biopsy-proven or suspicious for malignancy were enrolled in an NIR imaging clinical trial. Patients received a range of ICG doses 1 day before surgery: 1 mg/kg (n = 8), 2 mg/kg (n = 8), 3 mg/kg (n = 13), 4 mg/kg (n = 8), and 5 mg/kg (n = 8). Intraoperatively, NIR imaging was performed. The endpoint was to identify the highest tumor-to-background fluorescence ratio (TBR) for each tumor type at each dose. Final pathology confirmed tumor histology. RESULTS: Of 45 patients, 41 had malignancies (18 non-small cell lung cancers [NSCLC], 3 pulmonary neuroendocrine tumors, 13 thoracic metastases, 4 thymomas, 3 mesotheliomas). At doses of 4 to 5 mg/kg, the TBR from primary NSCLC vs other malignancies was no different (2.70 vs 3.21, p = 1.00). At doses of 1 to 3 mg/kg, the TBR was greater for the NSCLCs (3.19 vs 1.49, p = 0.0006). Background fluorescence from the heart or ribs was observed in 1 of 16 cases at 1 to 2 mg/kg, 5 of 13 cases at 3 mg/kg, and 14 of 16 cases at 4 to 5 mg/kg; this was a major determinant of dose optimization. CONCLUSIONS: This is the first study to demonstrate that the optimal NIR contrast agent dose varies by tumor histology. Lower dose ICG (2 to 3 mg/kg) is superior for nonprimary lung cancers, and high dose ICG (4 to 5 mg/kg) is superior for lung cancers. This will have major implications as more intraoperative imaging trials surface in other specialties, will significantly reduce costs and may facilitate wider application.
BACKGROUND: Near-infrared (NIR) imaging using the second time window of indocyanine green (ICG) allows localization of pulmonary, pleural, and mediastinal malignancies during surgery. Based on empirical evidence, we hypothesized that different histologic tumor types fluoresce optimally at different ICG doses. STUDY DESIGN:Patients with thoracic tumors biopsy-proven or suspicious for malignancy were enrolled in an NIR imaging clinical trial. Patients received a range of ICG doses 1 day before surgery: 1 mg/kg (n = 8), 2 mg/kg (n = 8), 3 mg/kg (n = 13), 4 mg/kg (n = 8), and 5 mg/kg (n = 8). Intraoperatively, NIR imaging was performed. The endpoint was to identify the highest tumor-to-background fluorescence ratio (TBR) for each tumor type at each dose. Final pathology confirmed tumor histology. RESULTS: Of 45 patients, 41 had malignancies (18 non-small cell lung cancers [NSCLC], 3 pulmonary neuroendocrine tumors, 13 thoracic metastases, 4 thymomas, 3 mesotheliomas). At doses of 4 to 5 mg/kg, the TBR from primary NSCLC vs other malignancies was no different (2.70 vs 3.21, p = 1.00). At doses of 1 to 3 mg/kg, the TBR was greater for the NSCLCs (3.19 vs 1.49, p = 0.0006). Background fluorescence from the heart or ribs was observed in 1 of 16 cases at 1 to 2 mg/kg, 5 of 13 cases at 3 mg/kg, and 14 of 16 cases at 4 to 5 mg/kg; this was a major determinant of dose optimization. CONCLUSIONS: This is the first study to demonstrate that the optimal NIR contrast agent dose varies by tumor histology. Lower dose ICG (2 to 3 mg/kg) is superior for nonprimary lung cancers, and high dose ICG (4 to 5 mg/kg) is superior for lung cancers. This will have major implications as more intraoperative imaging trials surface in other specialties, will significantly reduce costs and may facilitate wider application.
Authors: Jarrod D Predina; Andrew D Newton; Christopher Corbett; Leilei Xia; Michael Shin; Lydia Frenzel Sulfyok; Olugbenga T Okusanya; Keith A Cengel; Andrew Haas; Leslie Litzky; John C Kucharczuk; Sunil Singhal Journal: Ann Thorac Surg Date: 2018-07-17 Impact factor: 4.330
Authors: Jarrod D Predina; Andrew D Newton; Jane Keating; Ashley Dunbar; Courtney Connolly; Michael Baldassari; Jack Mizelle; Leilei Xia; Charuhas Deshpande; John Kucharczuk; Philip S Low; Sunil Singhal Journal: Ann Thorac Surg Date: 2018-02-15 Impact factor: 4.330
Authors: Olugbenga T Okusanya; David Holt; Daniel Heitjan; Charuhas Deshpande; Ollin Venegas; Jack Jiang; Ryan Judy; Elizabeth DeJesus; Brian Madajewski; Kenny Oh; May Wang; Steven M Albelda; Shuming Nie; Sunil Singhal Journal: Ann Thorac Surg Date: 2014-08-05 Impact factor: 4.330
Authors: Jack X Jiang; Jane J Keating; Elizabeth M De Jesus; Ryan P Judy; Brian Madajewski; Ollin Venegas; Olugbenga T Okusanya; Sunil Singhal Journal: Am J Nucl Med Mol Imaging Date: 2015-06-15
Authors: Venu G Bandi; Michael P Luciano; Mara Saccomano; Nimit L Patel; Thomas S Bischof; Jakob G P Lingg; Peter T Tsrunchev; Meredith N Nix; Bastian Ruehle; Chelsea Sanders; Lisa Riffle; Christina M Robinson; Simone Difilippantonio; Joseph D Kalen; Ute Resch-Genger; Joseph Ivanic; Oliver T Bruns; Martin J Schnermann Journal: Nat Methods Date: 2022-02-28 Impact factor: 47.990
Authors: Feredun Azari; Gregory T Kennedy; Kevin Zhang; Elizabeth Bernstein; Robert G Maki; Colleen Gaughan; Doraid Jarrar; Taine Pechet; John Kucharczuk; Sunil Singhal Journal: J Am Coll Surg Date: 2022-05-01 Impact factor: 6.532
Authors: Nicholas E Wojtynek; Madeline T Olson; Timothy A Bielecki; Wei An; Aaqib M Bhat; Hamid Band; Scott R Lauer; Edibaldo Silva-Lopez; Aaron M Mohs Journal: Mol Imaging Biol Date: 2020-08 Impact factor: 3.488
Authors: Syed Muhammad Usama; Sierra C Marker; Servando Hernandez Vargas; Solmaz AghaAmiri; Sukhen C Ghosh; Naruhiko Ikoma; Hop S Tran Cao; Martin J Schnermann; Ali Azhdarinia Journal: Cancers (Basel) Date: 2022-03-23 Impact factor: 6.639
Authors: Lisanne K A Neijenhuis; Lysanne D A N de Myunck; Okker D Bijlstra; Peter J K Kuppen; Denise E Hilling; Frank J Borm; Danielle Cohen; J Sven D Mieog; Willem H Steup; Jerry Braun; Jacobus Burggraaf; Alexander L Vahrmeijer; Merlijn Hutteman Journal: Life (Basel) Date: 2022-03-17